Key result
Tocilizumab combined with methylprednisolone and IVIG yielded 100% survival in severe acute necrotizing encephalopathy, while brainstem dysfunction predicted poorer outcomes (p=0.016).
Why the study?
The study aimed to compare clinical variables and various combinations of immunotherapy received with outcomes in patients with severe acute necrotizing encephalopathy.
Does tocilizumab combined with methylprednisolone and IVIG improve survival and functional outcomes in children with severe acute necrotizing encephalopathy?
Comparison
Tocilizumab combinations vs regimens without tocilizumab
Design
Multicentre retrospective case series review
Follow-up
6 months
Authors
Loading...
May guide immunotherapy selection in severe pediatric ANE; leaves open optimal regimens pending prospective trials.
Observational (n=27)
Yes
Does tocilizumab combined with methylprednisolone and IVIG improve survival and functional outcomes in children with severe acute necrotizing encephalopathy?
In a small multicenter case series, combination immunotherapy with tocilizumab, methylprednisolone, and IVIG showed a trend towards better survival in children with severe acute necrotizing encephalopathy.
Lee et al. (2023) conducted an observational in Severe acute necrotizing encephalopathy (ANE) (n=27). Tocilizumab (with or without methylprednisolone and IVIG) vs. No tocilizumab was evaluated on Outcomes based on the modified Rankin Scale. Tocilizumab combined with methylprednisolone and IVIG yielded 100% survival in severe acute necrotizing encephalopathy, while brainstem dysfunction predicted poorer outcomes (p=0.016).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: